Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.

Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product. Expert, hands-on guidance for managing and treating all major cancers-from the world-renowned physicians at The MD Anderson Cancer Center Comprehensive and authoritative, The MD Anderson Manual of Medical Oncology delivers everything you need to accurately diagnose and effectively treat a wide range cancers-including leukemia, lymphoma, myeloma, lung and breast cancer, genitourinary carcinoma, melanoma, and sarcoma. This unmatched resource emphasizes practical, actionable steps to cancer treatment, providing "to the point" recommendations, chapter summary boxes, tables, charts, expert opinion and patient education boxes, practice tips, cases, and prescriptive advice. And the new format of this updated edition quickly guides you to the topic, the affiliated relevant chapter, new findings affecting clinical practice, and reference/evidence. NEW format helps you get to the clinical bottom line quicker than ever NEW Q&A, cases, patient education information, expert advice, and more Expanded coverage of immunotherapy treatment-written by the 2018 Nobel Prize-winner for immunology Online content is continually updated Includes a comparative table with guidelines from the European Society of Medical Oncology and the American Society of Clinical Oncology

Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of new basic knowledge about the malignant process and about the potential for controlling these malignant diseases. Molecular Genetics and Therapy of Leukemia presents contributions by leading investigators and scientific contributors to such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, the p-53 suppressor gene and oncogene, hematopoietic stem cells, cytokines, detection of minimal residual disease in acute lymphoblastic leukemia, autologous marrow transplantation, the retinoblastoma gene, allogeneic bone marrow transplant and chemotherapy of acute lymphoblastic leukemia.

Leukemia is a malignant disease which continues to play a cutting edge role in the discovery of new basic knowledge about the malignant process and about the potential for controlling these malignant diseases. Molecular Genetics and Therapy of Leukemia presents contributions by leading investigators and scientific contributors to such topics as chromosome 16, chromosome 5, the BCL-2 gene, 11q23 breakpoint leukemias, the p-53 suppressor gene and oncogene, hematopoietic stem cells, cytokines, detection of minimal residual disease in acute lymphoblastic leukemia, autologous marrow transplantation, the retinoblastoma gene, allogeneic bone marrow transplant and chemotherapy of acute lymphoblastic leukemia.